Response Genetics Inc was incorporated in the State of Delaware on September 23, 1999. It is a life sciences company engaged in the research and development of clinical diagnostic tests for cancer. The Company currently generates revenues mainly from sales of its ResponseDX diagnostic tests, which it launched in 2008 and by providing clinical trial testing services to pharmaceutical companies. It has developed technologies for the extraction of RNA from FFPE tissues which enable it to reliably recover RNA suitable for a variety of applications, such as gene expression research, development of diagnostics, and microarray platforms. In addition, its technologies permit gene profiling analysis of current clinical trials, of which use the paraffin embedding technique for tissue specimen storage. The Company developed and patented extraction methodologies that allow reliable and consistent isolation of RNA and DNA from FFPE suitable for use in various types of analysis. The Company validated its methodology, which particularly addressed issues of recovery of RNA, accuracy, and precision. Further, its methodologies allow for rapid extraction of RNA with little or no DNA contamination, which makes it suitable for large-scale analysis. The Company developed ResponseDX in part by using its technology to extract genetic information from FFPE tumor specimens. Its technology provides gene expression information for each patient's tumor tissue specimen. It has developed assays for the targets comprising the ResponseDX profiles for use in its CLIA lab. Assay development of these tests was done through appropriate validation procedures which determine the accuracy of each test. The Company offers ResponseDX testing services nationwide. Its main sales include community based oncologists, pathologists, physician offices and hospitals. The Company's actual competitors in the United States and abroad may include clinical and pathology laboratories, such as Quest Diagnostics Inc., Laboratory Corporation of America, Clarient, Inc. (acquired by GE), and laboratories such as Genoptixs Inc. (acquired by Novartis Pharmaceuticals), NeoGenomics, Inc., Caris Life Sciences, Foundation Medicine, university laboratories and other research institutions. The Company is subject to various regulatory requirements designed to ensure the quality and integrity of its non-clinical testing processes. Its business is also subject to regulation under state and federal laws regarding environmental protection and hazardous substances control, such as the Federal Occupational Safety and Health Act, the Environmental Protection Act, and Toxic Substances Control Act.